DeepNovoV2: Better de novo peptide sequencing with deep learning
  Personalized cancer vaccines are envisioned as the next generation rational
cancer immunotherapy. The key step in developing personalized therapeutic
cancer vaccines is to identify tumor-specific neoantigens that are on the
surface of tumor cells. A promising method for this is through de novo peptide
sequencing from mass spectrometry data. In this paper we introduce DeepNovoV2,
the state-of-the-art model for peptide sequencing. In DeepNovoV2, a spectrum is
directly represented as a set of (m/z, intensity) pairs, therefore it does not
suffer from the accuracy-speed/memory trade-off problem. The model combines an
order invariant network structure (T-Net) and recurrent neural networks and
provides a complete end-to-end training and prediction framework to sequence
patterns of peptides. Our experiments on a wide variety of data from different
species show that DeepNovoV2 outperforms previous state-of-the-art methods,
achieving 13.01-23.95\% higher accuracy at the peptide level.
